A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer progressed on gemcitabine-based therapy.

Patrick Grierson,Andrea Wang-Gillam,Haeseong Park,Katrina Pedersen,Benjamin R. Tan,Manik Amin,Rama Suresh,Nikolaos A. Trikalinos,Jingxia Liu

A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer progressed on gemcitabine-based therapy.

2020

Patrick Grierson
Andrea Wang-Gillam
Haeseong Park
Katrina Pedersen
Benjamin R. Tan
Manik Amin
Rama Suresh
Nikolaos A. Trikalinos
Jingxia Liu

TPS793Background: Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second leading cause of cancer-related death by 2030, and is characterized by resistance to chemo- and radiotherapy ...

Keywords:

Pancreatic cancer
Gemcitabine
Internal medicine
Oncology
Liposomal Irinotecan
Medicine
Paricalcitol
Pathology
in patient
pancreatic ductal adenocarcinoma
Radiation therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations